JP2009544280A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544280A5
JP2009544280A5 JP2009519713A JP2009519713A JP2009544280A5 JP 2009544280 A5 JP2009544280 A5 JP 2009544280A5 JP 2009519713 A JP2009519713 A JP 2009519713A JP 2009519713 A JP2009519713 A JP 2009519713A JP 2009544280 A5 JP2009544280 A5 JP 2009544280A5
Authority
JP
Japan
Prior art keywords
gene
deletion
cfhr1
gene product
cfhr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009519713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544280A (ja
JP5431151B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/073514 external-priority patent/WO2008008986A2/en
Publication of JP2009544280A publication Critical patent/JP2009544280A/ja
Publication of JP2009544280A5 publication Critical patent/JP2009544280A5/ja
Application granted granted Critical
Publication of JP5431151B2 publication Critical patent/JP5431151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009519713A 2006-07-13 2007-07-13 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 Active JP5431151B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83101806P 2006-07-13 2006-07-13
US60/831,018 2006-07-13
US84007306P 2006-08-23 2006-08-23
US60/840,073 2006-08-23
PCT/US2007/073514 WO2008008986A2 (en) 2006-07-13 2007-07-13 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2009544280A JP2009544280A (ja) 2009-12-17
JP2009544280A5 true JP2009544280A5 (https=) 2010-09-02
JP5431151B2 JP5431151B2 (ja) 2014-03-05

Family

ID=38924245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519713A Active JP5431151B2 (ja) 2006-07-13 2007-07-13 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬

Country Status (11)

Country Link
US (4) US7867727B2 (https=)
EP (3) EP2479284B1 (https=)
JP (1) JP5431151B2 (https=)
AT (1) ATE551350T1 (https=)
AU (1) AU2007272335B2 (https=)
CA (1) CA2659392A1 (https=)
DK (1) DK2447275T3 (https=)
IL (1) IL196319A0 (https=)
NZ (1) NZ574046A (https=)
SG (1) SG173371A1 (https=)
WO (1) WO2008008986A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2357254A1 (en) * 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
AU2007277125B2 (en) * 2006-07-26 2013-08-01 Yale University Diagnosis and treatment of age related macular degeneration
EP2217720A4 (en) * 2007-11-01 2010-12-08 Univ Iowa Res Found RNA LOCUS ANALYSIS TO ASSESS THE STUNNING FOR AMD AND MPGNII
US20090186370A1 (en) * 2008-01-18 2009-07-23 Ogle Matthew F Diagnostic biomarkers for vascular aneurysm
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
US20120190578A1 (en) * 2009-08-06 2012-07-26 Washington University Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
EP2478377A2 (de) * 2009-09-14 2012-07-25 Mosaiques Diagnostics And Therapeutics AG Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen
JP5706612B2 (ja) * 2009-12-28 2015-04-22 学校法人 埼玉医科大学 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット
US20120202708A1 (en) * 2010-10-14 2012-08-09 Sequenom, Inc. Complement factor h copy number variants found in the rca locus
US9598733B2 (en) * 2011-02-17 2017-03-21 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing IgA nephropathy
CA2834676A1 (en) * 2011-04-29 2012-11-01 University Of Utah Research Foundation Methods of predicting the development of complement-mediated disease
JP2013064616A (ja) * 2011-09-15 2013-04-11 Osaka Univ 高度動脈硬化を発症している可能性を検出する方法およびその利用
WO2013150132A2 (de) * 2012-04-05 2013-10-10 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung von schlaganfällen
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
EP2962106A1 (en) * 2013-02-26 2016-01-06 Roche Diagnostics GmbH Agents, kits and methods for complement factor h-related protein 1 detection
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
WO2014194213A1 (en) * 2013-05-30 2014-12-04 University Of Iowa Research Foundation Specific complement proteins and efficacy of antibody therapy
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
JP7199966B2 (ja) 2015-12-23 2023-01-06 ソルボンヌ ウニベルシテ ＣＤ１１ｂ／ＣＤ１８に対するＣＦＨの結合を阻害する薬剤、およびその使用
CA3023802C (en) 2016-05-10 2025-02-04 Inserm (Institut De La Sante Et De La Recherche Medicale) ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3791180A1 (en) * 2018-05-10 2021-03-17 The University Of Manchester Methods for assessing macular degeneration
EP3824095A4 (en) 2018-07-20 2022-04-20 University of Utah Research Foundation GENE THERAPY FOR MACULATE GENERATION
DE102018120016B4 (de) 2018-08-16 2020-09-03 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung
WO2020180147A2 (ko) * 2019-03-07 2020-09-10 (주)레티마크 나이관련 황반변성 진단용 복합 마커 및 이의 용도
WO2020210724A1 (en) 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
CA3158517A1 (en) * 2019-10-22 2021-04-29 Applied Genetic Technologies Corporation Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders
WO2022058447A1 (en) * 2020-09-16 2022-03-24 The University Of Manchester Complementome assay

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
EP0681482B1 (en) 1993-01-22 2005-12-07 University Research Corporation Localization of therapeutic agents
US5667969A (en) 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
NZ507093A (en) 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
AU3704500A (en) 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
AU2001261103B2 (en) 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
WO2003016470A2 (en) 2001-08-10 2003-02-27 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
CN102618644A (zh) * 2004-11-18 2012-08-01 耶鲁大学 治疗眼病的方法和组合物
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
EP2570491A1 (en) 2005-06-08 2013-03-20 University of Pittsburgh of the Commonwealth System of Higher Education Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
KR20080065657A (ko) 2005-10-11 2008-07-14 예일 유니버시티 황반 변성 관련 유전자
US20080255000A1 (en) 2005-11-02 2008-10-16 Dogulu Cigdem F Method Evolved for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd)
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
GB0611606D0 (en) * 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration

Similar Documents

Publication Publication Date Title
JP2009544280A5 (https=)
JP5431151B2 (ja) 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬
Kerlin et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia
EP3811972B1 (en) Combination therapy for treatment of atherosclerosis
JP2007506426A5 (https=)
Zorzetto et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis
CN105431549A (zh) 癌症中的tert(端粒酶逆转录酶)基因启动子突变
Zepp et al. TRAF4-SMURF2–Mediated DAZAP2 degradation is critical for IL-25 signaling and allergic airway inflammation
JP2003508022A5 (https=)
WO2012107580A1 (en) In vitro diagnosis method for predicting a predisposition to cardiomyopathy
US20180258484A1 (en) Inflammation-enabling polypeptides and uses thereof
JP4779115B2 (ja) 早期肺癌の術後予後検査方法
JP2020530978A (ja) Ｈｌａ−ｇ転写物およびアイソフォームおよびそれらの使用
EP2855516B1 (en) Inflammation-enabling polypeptides and uses thereof
JP2018504909A5 (https=)
WO2016122865A1 (en) Compositions and methods for treating age-related diabetes and related disorders
CN102947446A (zh) 肺腺癌的预后预测方法、肺腺癌的检测试剂盒以及用于治疗肺腺癌的医药组合物
Asselta et al. Missense or splicing mutation? The case of a fibrinogen Bβ-chain mutation causing severe hypofibrinogenemia
Singh et al. Multi-exon out of frame deletion of the FBN1 gene leading to a severe juvenile onset cardiovascular phenotype in Marfan syndrome
Chen et al. von Willebrand factor variants in C3 glomerulopathy: a Chinese cohort study
JP2006516888A5 (https=)
US20160326585A1 (en) Inflammation-enabling polypeptides and uses thereof
CN108752452B (zh) Sars及其突变体的应用
JP4471803B2 (ja) 全身性エリテマトーデス患者血液細胞で発現亢進している遺伝子群、およびその利用
US6664052B1 (en) Genetic polymorphism in a complement receptor